Let's put aside all prejudices and stereotypes about domestic medicine for a moment and try to objectively understand what was done right and what was wrong with the "world's first vaccine against COVID" - Sputnik V from the "Research Institute of Epidemiology and Microbiology. N. Gamalei ".

Let's talk about how modern science works in general and evidence-based medicine in particular, and what does PR have to do with it.

Evidence-based medicine

The current scientific consensus is the need for clinical trials to follow a well-defined protocol. Clinical trials in Russia are systematically carried out in violation of this protocol, which leads to the widespread use of drugs with "unproven efficacy" (aka "fuflomycins").

According to various estimates, the domestic regulator, represented by the Ministry of Health, either ignores the problem or condones . A textbook example is Arbidol. A drug that shows antiviral activity in vitro, but has no proven therapeutic effect in the body for any infection. Regular conflicts between the Ministry of Health and the FAS around Arbidol led (among other things) to the recent resignation of the head of the FAS Artemyev.

Undermined authority

, . , . , Pfizer ( ) . ( , ) ", ".

, "" . — FDA. ( !) . - , , , , . : , , FDA. .

FDA, :

, . , , — . , «» .



- FDA , , 20-, 80 . , , , , . . , - . , , — . , , . . .

, " , ". , , "-" , . "" , . , 100 — "" . - , "", — . , , .

.

. , . — "". , , " V". " ".

" V"

, . , . , " ". , ""...

" "

, . , "" . . " " . - .

" "

, . , — . "" . , "" .

Lancet

, - (. . -: ). ( ), " , ". , " , ", . : . , . . , , , .

" " .

, . -, : . " , ". , , .

-, , "" (.. , , ) . , "" . , . , . , ( , ). , , , .. .

: . . . " ". . , , " ", , , .

"92% ". , . . 20 ( , . . ) 26%-92%. 95% . "92%" — .

Pfizer, 90% 94 ( FDA — 93, , - ) . . . : 86.6%-97.7% ( 80,8 95,5). 90%. , .

, " ". 50-60% .

. . , ( ).

. . — . , . . — .

, .

. . 60- . , , , .

, , " ". " " , . . .

, " V" ( !). , ( ).

, " " - , , , , . ( Pfizer, , , ), - , - "".

, , " ". , " V" — " ": , . . .

,

, 40% "", 25% . , " !". . …

"" , !

, . , - . , .

...

. !